FDA
- Status: approved
12 months of P2Y12 receptor antagonist (12 months of P2Y12 receptor antagonist) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Beijing Anzhen Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.